Mylan settles cancer drug patent dispute with Genentech
Mylan has entered a settlement with Genentech and its parent company, Roche, in relation to patents for cancer drug Herceptin (trastuzumab).
According to a statement released yesterday, March 14, Mylan now has a global licence for its biosimilar product.
The licence will allow Mylan to commercialise its product around the world apart from in Japan, Brazil and Mexico.
As part of the settlement, Mylan has agreed to withdraw its pending inter partes review challenges against Genentech concerning US patent numbers 6,407,213 and 6,331,415.
Mylan said that it expects to be potentially the first company to launch a Herceptin biosimilar in the US.
Heather Bresch, CEO of Mylan, said: "There is an unmet need for access to more affordable versions of biologic products such as trastuzumab.”
She added that with 16 biosimilar products in development, Mylan has one of the industry's broadest portfolios of biosimilars.
Mylan currently has exclusive commercialisation rights for the proposed biosimilar trastuzumab in the US, Canada, Japan, Australia, New Zealand, the EU and European Free Trade Association.
Biocon, an India-based biopharmaceutical company, has co-exclusive commercialisation rights with Mylan for the product in the rest of the world.
Mylan's Biologics License Application for the proposed biosimilar of trastuzumab is currently being reviewed by the US Food and Drug Administration.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk